These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Kaplan MM; Poupon R Hepatology; 2009 Aug; 50(2):652. PubMed ID: 19309721 [No Abstract] [Full Text] [Related]
7. Pretransplant ursodeoxycholic acid therapy and liver transplantation in patients with primary biliary cirrhosis: win, win, win? Benner KG Liver Transpl Surg; 1999 Jul; 5(4):334-7. PubMed ID: 10388507 [No Abstract] [Full Text] [Related]
8. How, why, and when does primary biliary cirrhosis recur after liver transplantation? Williams R; Gershwin ME Liver Transpl; 2007 Sep; 13(9):1214-6. PubMed ID: 17763403 [No Abstract] [Full Text] [Related]
10. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Lindor K N Engl J Med; 2007 Oct; 357(15):1524-9. PubMed ID: 17928600 [No Abstract] [Full Text] [Related]
11. Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems. Goel A; Kim WR Clin Liver Dis; 2018 Aug; 22(3):563-578. PubMed ID: 30259853 [TBL] [Abstract][Full Text] [Related]
12. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Corpechot C; Poupon R Hepatology; 2007 Oct; 46(4):963-5. PubMed ID: 17894325 [No Abstract] [Full Text] [Related]
13. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. Joshita S; Umemura T; Ota M; Tanaka E J Hepatol; 2014 Dec; 61(6):1443-5. PubMed ID: 25152209 [No Abstract] [Full Text] [Related]
15. Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future? Gluud C; Christensen E J Hepatol; 2001 May; 34(5):787-8. PubMed ID: 11434634 [No Abstract] [Full Text] [Related]
16. Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit. Schattenberg JM Gut; 2020 Aug; 69(8):1377-1378. PubMed ID: 32205421 [No Abstract] [Full Text] [Related]
17. Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis". Trivedi PJ; Bruns T; Li KK; Hirschfield GM J Hepatol; 2014 Dec; 61(6):1445-6. PubMed ID: 25152206 [No Abstract] [Full Text] [Related]
18. Management of primary biliary cirrhosis: from diagnosis to end-stage disease. Lazaridis KN; Lindor KD Curr Gastroenterol Rep; 2000 Apr; 2(2):94-8. PubMed ID: 10981009 [TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of primary biliary cirrhosis. Ali AH; Carey EJ; Lindor KD Expert Rev Clin Immunol; 2014 Dec; 10(12):1667-78. PubMed ID: 25382237 [TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. Paumgartner G J Hepatol; 2003 Jul; 39(1):112-4. PubMed ID: 12821052 [No Abstract] [Full Text] [Related] [Next] [New Search]